Sanofi has received orphan designation from the EMA for rilzabrutinib, a reversible covalent BTK inhibitor, to treat IgG4-RD.

Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...

EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The company plans to launch the first version of its AI Advocate tool, aimed at helping patients manage and guide their ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Rilzabrutinib: Sanofi BOXABAN (Ifetroban): Cumberland Pharmaceuticals RG6341 (GDC-6599): Genentech Research/Roche CBP-201: Suzhou Connect Biopharmaceuticals AVTX-002 (Quisovalimab): Avalo Therapeutics ...